THE VIRILITY SOLUTION: THE BRITISH CONNECTION

The next occurrence of timing and luck that was leading researchers ever closer to an oral cure for ED came with the discovery of unexpected and ultimately useful side effects of other medications. In the early 1990s, researchers working in England, at the Sandwich Laboratories of Pfizer Inc., the American-based pharmaceutical company, were delving into gene receptors. Their goal was to find a way to increase blood flow in the body, thereby easing the pain associated with angina pectoris, a prominent symptom of a cardiac condition known as myocardial ischemia. This condition occurs when the heart muscle is deprived of the blood it requires.

As it turned out, the drug they were experimenting with had a very minor impact on the circulation and heart function of the study’s volunteers. But as a last effort, the researchers decided to alter the dose regimen to see if it would make any difference. And indeed it did—but not the way the scientists expected it to. UK-92-480 didn’t affect blood flow to the chest; it affected blood flow to the penis, resulting in erections.

The Pfizer researchers quickly switched the primary focus of their investigations to the process by which certain enzymes in the body help trigger an erection. The more they experimented with UK-92-480, the code name for the drug that was to be called sildenafil, and later to be given the brand name of Viagra, the more they realized that they had inadvertently stumbled upon something totally new in the annals of medicine. It seemed they discovered a powerful and effective medication for producing erections.

*32\183\8*

Related Posts:

• SKIN INFECTIONS
• HYPOTHYROIDISM
• EYE DISORDERS: DIABETES MELLITUS AND VISION PROBLEMS
• GASTROINTESTINAL CANCER: STOMACH AND LIVER CANCER
• HOW IS AIDS DIAGNOSED?
• THE VIRILITY SOLUTION: AND THERE WAS ALWAYS ALCOHOL